Lonza’s announcement of a new spray-drying facility in Bend, Oregon, underscores its strategic focus on high-margin medicines and the U.S. market. This investment not only enhances Lonza’s capabilities in complex therapies but also signifies a robust commitment to expanding its footprint in a region that is increasingly vital for pharmaceutical manufacturing. Concurrently, CordenPharma is ramping up its operations with an €80 million investment aimed at scaling its injectable capacity, reflecting a broader trend within the industry towards enhancing production capabilities for essential drug forms.
These developments come at a time when the demand for advanced drug formulations is surging, driven by a growing emphasis on personalized medicine and biologics. For both companies, these expansions are not merely operational upgrades; they are strategic maneuvers to position themselves as leaders in a competitive landscape. The implications for regulatory compliance, quality assurance, and supply chain management will be significant, as both firms navigate the complexities of scaling operations while adhering to stringent industry standards.
Open the full market picture for your next decision →
